DMPA-SC Evidence to Practice: Increasing access, empowering women

June 18, 2018 by PATH

Participants at the DMPA-SC Evidence to Practice workshop in May 2018

Participants at the DMPA-SC Evidence to Practice workshop in May 2018. Photo: PATH

The DMPA-SC Evidence to Practice workshop was held in May 2018 with the goal of increasing voluntary and high-quality access to DMPA-SC within a wide range of contraceptive methods.

Co-hosted by PATH and the Kenya Ministry of Health, the Evidence to Practice workshop involved more than 175 participants from 20+ countries, including ministry of health representatives, implementing partners, and donors.

Workshop participants shared the latest evidence regarding DMPA-SC* (brand name Sayana® Press) and self-injection, and developed country action plans. In addition, two regional DMPA-SC Learning and Action Networks—one Anglophone and one Francophone—were launched under the DMPA-SC Access Collaborative to sustain connections and facilitate evidence-based progress across countries.

A meeting report as well as evidence and related resources featured at the workshop are highlighted below. For more information, sign up for our newsletter or email FPoptions@path.org.

Overview and resources

Effective delivery of DMPA-SC

Self-injection: Acceptability, feasibility, and effectiveness

Workshop presentations

“ We have moved beyond the period of pilots and studies—countries need to move to planning for ambitious scale up and use a cascade approach to train providers swiftly. ”
— Evidence to Practice workshop participant

*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate.
Sayana Press is a registered trademark of Pfizer Inc.
Uniject is a trademark of BD.

Read More